BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Lobbying for BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
Annual FY26 appropriations for FDA, NIH, HHS, and DOD
HR 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14; HR 379, Healthcare Freedom and Choice Act; HR 483, Health Care Efficiency through Flexibility Act; HR 1509/S 752, Accelerating Kids' Access to Care Act; HR 1262/S 932, Give Kids a Chance Act; HR 2528, Association Health Plans Act; Draft legislation related to promoting investment in pediatric cancer drug development; Draft legislation related to promoting access to clinical trials; Pharmacy Benefit Manager reforms; Anti-competitive contracting reforms; CFPB medical debt regulations;
HR 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14, specifically Subtitle B health provisions; Site-neutral payment reforms in Medicare;
Preventing Executive Branch rescissions and suspensions of NIH grants/grant funds; Education re the importance of staff roles within health agencies
HR 247/S 46, the Health Care Affordability Act; HR 801/S 317, Charitable Act HR 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14, specifically provisions related to tax treatment of charitable giving